Ongoing Assessments & Recent Research.
Easy access to our work
Spinal Muscular Atrophy
Aug 2025Multiple Sclerosis: SPMS
Jun 2025Acute Pain
Feb 2025Retinitis Pigmentosa
Apr 2025Featured News & Insights.
Learn about our latest work.
Institute for Clinical and Economic Review to Assess Treatments for Spinal Muscular Atrophy
Report will be subject of Midwest CEPAC meeting in August 2025; Draft Scoping Document open to public comment until January 27, 2025.
01/06/2025Institute for Clinical and Economic Review Publishes Fourth Annual Assessment of Barriers to Fair Access Within US Commercial Insurance Prescription Drug Coverage
Most payers evaluated offer fair access across the domains reviewed; findings underscore the need for greater transparency of coverage policy information for patients.
12/19/2024Institute for Clinical and Economic Review Publishes Final Evidence Report on Treatment for Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease
Independent appraisal committee voted that current evidence is adequate to demonstrate superior net health benefits for tabelecleucel when compared to usual care; tabelecleucel would achieve common thresholds for cost-effectiveness if priced between $143,900 to $273,700 per treatment cycle.
12/16/2024Our Origin Story.
Dr. Steve Pearson explains why he founded an organization to advance the use of evidence to improve health care affordability and access for all patients and their families.
The ICER Impact.
New York Medicaid pursued discounts, many of which were in line with ICER reports, which have saved the state over $500 million
Engaged with over 400 patient groups and patient reps
In a landmark international program, HTA agencies around the world can now access ICER’s customizable COVID-19 Cost-Effectiveness Model
Key
Developments.
The ICER-developed Clinical trial Diversity Rating (CDR) Tool presents a framework for evaluating the demographic diversity of clinical trial populations in a consistent, transparent manner leading to an overall diversity rating. Learn more.
In 2025, NICE announced a collaboration with several HTA organizations to share a new guidance on the use of surrogate endpoints to inform decision-making when evaluating new medicines.
The ICER Patient Council met in 2024 to discuss ICER’s patient engagement activities over the last year and to make an action plan for the next 12 months. One output of that meeting was the ICER Patient Council Progress Report, which describes the various projects the Council has reviewed and advised to enhance ICER’s Patient Engagement Program.
Current
Policy Papers.
Easy access to our latest policy papers
Barriers to Fair Access
ICER’s fourth annual “Barriers to Fair Access” assessment of prescription drug coverage policies within US commercial insurance, and the Veterans Health Administration. The analysis found that major payer coverage policies for 11 drugs often met fair access criteria for cost sharing, clinical eligibility, step therapy, and provider restrictions.
However, the report’s findings suggest that major improvements are needed in the transparency of coverage policy information for consumers, and in detailing out-of-pocket costs for patients.
Unsupported Price Increases
Of 10 high-expenditure drugs that had substantial 2023 net price increases, five were not supported by new clinical evidence; these increases accounted for $815 million in additional costs in 2023.The five drugs with unsupported price increases are Biktarvy, Darzalex, Entresto, Cabometyx, and Xeljanz.
Managing the Challenges of Paying for Gene Therapy
An analysis of policy reforms and market actions to support innovation and access while managing uncertainty, affordability, and equity concerns; developed as part of ICER’s Policy Leadership Forum with input from diverse stakeholders.